Project Leader(s): Dr Barber
We are aiming to recruit patients to this 20 month, Phase III, multicentre, randomized, double-blind, placebo-controlled trial of bapineuzumab in subjects with Alzheimer’s disease. The study will aim to determine the efficacy and safety of bapineuzumab.
Bapineuzumab is a form of passive amyloid immunisation for Alzheimer’s disease, and participants will receive an amyloid antibody or placebo infusion every 13 weeks, with safety monitoring including MRI scans. Various standardized assessment scales and other physical tests are also conducted to help evaluate the impact of the treatment.
The main inclusion criteria include a diagnosis of Alzheimer’s disease of mild to moderate severity (MMSE 16-26), regular contact with a caregiver, no contra-indications to MRI scan and a stable medication regime.
The study is being conducted in collaboration between CARU and the Dementias & Neurodegenerative Diseases Research Network (DeNDRoN).
Consultant in Old Age Psychiatry